alendronate has been researched along with Chondrodystrophic Myotonia in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 7.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 3.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onuchic, L | 1 |
| Ferraz-de-Souza, B | 1 |
| Mendonca, BB | 1 |
| Correa, PH | 1 |
| Martin, RM | 1 |
1 other study available for alendronate and Chondrodystrophic Myotonia
| Article | Year |
|---|---|
Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Drug Therapy, Combina | 2012 |